Literature DB >> 22343491

Cyr61 is a potential prognostic marker for prostate cancer.

Naoki Terada1, Prakash Kulkarni, Robert H Getzenberg.   

Abstract

Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling that is frequently altered in expression in several types of cancers. In prostate cancer (PCa), Cyr61 is highly expressed in organ-confined disease. Further, Cyr61 expression levels are associated with a lower risk of disease recurrence, and can be quantitatively measured in the serum. Considered together, these results indicate that Cyr61 is a potential and clinically useful tissue, as well as serum-based biomarker for differentiating lethal and non-lethal PCa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343491      PMCID: PMC3472413          DOI: 10.1038/aja.2011.149

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  43 in total

1.  Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer.

Authors:  Daniel R Rhodes; Terrence R Barrette; Mark A Rubin; Debashis Ghosh; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

2.  Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features.

Authors:  D Xie; K Nakachi; H Wang; R Elashoff; H P Koeffler
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

3.  Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays.

Authors:  Kulkarni Prakash; Gregorio Pirozzi; Michael Elashoff; William Munger; Iwao Waga; Rajiv Dhir; Yoshiyuki Kakehi; Robert H Getzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

4.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.

Authors:  A W Partin; L A Mangold; D M Lamm; P C Walsh; J I Epstein; J D Pearson
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

5.  Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer.

Authors:  X Tong; D Xie; J O'Kelly; C W Miller; C Muller-Tidow; H P Koeffler
Journal:  J Biol Chem       Date:  2001-10-11       Impact factor: 5.157

6.  Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease.

Authors:  D Xie; C W Miller; J O'Kelly; K Nakachi; A Sakashita; J W Said; J Gornbein; H P Koeffler
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

7.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients.

Authors:  Gerald W Hull; Farhang Rabbani; Farhat Abbas; Thomas M Wheeler; Michael W Kattan; Peter T Scardino
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

8.  Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.

Authors:  Jun Luo; Shan Zha; Wesley R Gage; Thomas A Dunn; Jessica L Hicks; Christina J Bennett; Charles M Ewing; Elizabeth A Platz; Sacha Ferdinandusse; Ronald J Wanders; Jeffrey M Trent; William B Isaacs; Angelo M De Marzo
Journal:  Cancer Res       Date:  2002-04-15       Impact factor: 12.701

9.  alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.

Authors:  Mark A Rubin; Ming Zhou; Saravana M Dhanasekaran; Sooryanarayana Varambally; Terrence R Barrette; Martin G Sanda; Kenneth J Pienta; Debashis Ghosh; Arul M Chinnaiyan
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

10.  alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.

Authors:  Rainer Kuefer; Sooryanarayana Varambally; Ming Zhou; Peter C Lucas; Martin Loeffler; Hubertus Wolter; Torsten Mattfeldt; Richard E Hautmann; Juergen E Gschwend; Terrence R Barrette; Rodney L Dunn; Arul M Chinnaiyan; Mark A Rubin
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

View more
  16 in total

1.  Cyr61 promotes growth of glioblastoma in vitro and in vivo.

Authors:  Gang Cheng; Hangyu Zhang; Leiming Zhang; Jianning Zhang
Journal:  Tumour Biol       Date:  2014-12-14

2.  TET1-mediated different transcriptional regulation in prostate cancer.

Authors:  Jianhua Feng; Qiang Wang; Guangwei Li; Xiangjian Zeng; Shihang Kuang; Xiaohua Li; Youwei Yue
Journal:  Int J Clin Exp Med       Date:  2015-01-15

3.  Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.

Authors:  Y F Song; Z B Xu; X J Zhu; X Tao; J L Liu; F L Gao; C L Wu; B Song; Q Lin
Journal:  Clin Transl Oncol       Date:  2016-10-14       Impact factor: 3.405

4.  Cyr61 promotes growth of pancreatic carcinoma via nuclear exclusion of p27.

Authors:  Weidong Shi; Jianhua Yin; Zhen Chen; Hao Chen; Luming Liu; Zhiqiang Meng
Journal:  Tumour Biol       Date:  2014-08-08

5.  Overexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes.

Authors:  Zhi Cao; Yang Wang; Zhi-Yong Liu; Zhen-Sheng Zhang; Shan-Cheng Ren; Yong-Wei Yu; Meng Qiao; Bei-Bei Zhai; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2013-08-26       Impact factor: 3.285

6.  Cyr61: a potential therapeutic target for prostate cancer.

Authors:  Chang-Ming Lin; Chao-Zhao Liang
Journal:  Asian J Androl       Date:  2014 Sep-Oct       Impact factor: 3.285

7.  Dexamethasone Inhibits TGF-β1-Induced Cell Migration by Regulating the ERK and AKT Pathways in Human Colon Cancer Cells Via CYR61.

Authors:  Sanghoon Han; Ngoc Thuy Bui; Manh Tin Ho; Young Mee Kim; Moonjae Cho; Dong Bok Shin
Journal:  Cancer Res Treat       Date:  2015-12-15       Impact factor: 4.679

8.  Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor.

Authors:  Ling-Yu Chu; Jian-Yuan Zhou; Yi-Xuan Zhao; Yan-Ting Ou; Tian Yang; Yu-Hui Peng; Wang-Kai Fang; Yi-Wei Xu; Jian-Jun Xie
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

9.  WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone.

Authors:  Mitsuaki Ono; Colette A Inkson; Robert Sonn; Tina M Kilts; Luis F de Castro; Azusa Maeda; Larry W Fisher; Pamela G Robey; Agnes D Berendsen; Li Li; Nancy McCartney-Francis; Aaron C Brown; Nigel P S Crawford; Alfredo Molinolo; Alka Jain; Neal S Fedarko; Marian F Young
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

10.  Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells.

Authors:  Carmen P Wong; Anna Hsu; Alex Buchanan; Zoraya Palomera-Sanchez; Laura M Beaver; E Andres Houseman; David E Williams; Roderick H Dashwood; Emily Ho
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.